tanzania times : Latest News and In-depth Analysis
Contact Us
Search

Depth

tanzania times : Latest News and In-depth Analysis
HomeDepth
Depth

Mar 5, 2025

TCL Launches First AI-Powered Tablet, the TCL NXTPAPER 11 Plus, at MWC - Bringing Unparalleled Versatility, Personalization and Comfort

BARCELONA,Spain,March 3,2025-- TCL,a pioneer in display across feature-rich smartphones,tablets,and connected devices,today announced the launch of the TCL NXTPAPER 11 Plus Tablet at Mobile World Cong

All News

Depth

Pantai Hospital Kuala Lumpur and IMU University Sign MoU to Advance Medical Research and Education

KUALA LUMPUR,Malaysia,March 5,2025-- Pantai Hospital Kuala Lumpur (PHKL) and IMU University have officially entered into a five-year Memorandum of Understanding (MoU) to foster collaboration in biomed

Mar 5, 2025

Depth

LONGi's "Lighthouse Factory" was fully upgraded, HPBC 2.0 production line put into operation

XI\'AN,China,Feb. 27,2025-- On February 25,LONGi held the "HPBC 2.0 \'Lighthouse Factory\' Media Tour" at the Jiaxing base,which is the first time that the HPBC 2.0 production line has been

Feb 28, 2025

Depth

YUEWEN WONDERLAND Daily Footfall Surpasses 20K+ Visitors as 'Goods Economy' Ignites Singapore

SINGAPORE,Feb. 27,2025--The one-month-longYUEWEN WONDERLAND event at Marina Bay Sands culminated successfully,marking a significant milestone in cross-cultural IP activation. Leveraging Yuewen\'s vast

Feb 28, 2025

Daqo New Energy Announces Unaudited Fourth Quarter and Fiscal Year 2024 Results

SHANGHAI,Feb. 27,2025-- Daqo New Energy Corp. (NYSE: DQ) ("Daqo New Energy," the "Company" or "we"),a leading manufacturer of high-purity polysilicon for the global solar

Feb 28, 2025

Akeso Announces First ADC Drug Clinical Trial, Marking a New Era for "IO 2.0 + ADC" Strategy

HONG KONG,Feb. 27,2025-- Akeso,Inc. (9926.HK) announced the first patient has been enrolled in the Phase I clinical trial of AK138 D1 for the treatment of advanced malignancies in Australia. AK138D1,a

Feb 28, 2025

Depth

CARsgen's Allogeneic CD19/CD20 CAR-T Therapy Administers First Dose in a Patient with Autoimmune Disease

SHANGHAI,Feb. 28,2025-- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK),a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors

Feb 28, 2025

1 2 3 4 5 ... 65